Shares of Tempus AI (TEM) plummeted 13.78% in Monday's after-hours trading session, following the company's release of disappointing fourth-quarter results and wider-than-expected annual losses for 2024.
The precision medicine technology firm reported Q4 revenue of $200.7 million, up 35.8% year-over-year, but missed analyst estimates of $203.1 million. For the full year 2024, revenue increased 30.4% to $693.4 million, driven by strong growth in both the Genomics and Data and Services segments.
However, Tempus AI's Q4 adjusted net loss widened to $0.18 per share from $0.15 per share a year earlier, missing analyst expectations of a $0.16 loss. The company reported a net loss of $705.8 million for the full year, significantly wider than the $214.1 million loss in 2023, largely due to $547.7 million in stock-based compensation expenses.
The wider-than-expected losses overshadowed Tempus AI's solid revenue growth and operational achievements in 2024, such as the acquisition of Ambry Genetics and the launch of FDA-approved diagnostic products. While the company raised its 2025 revenue guidance to $1.24 billion, representing 79% annual growth, and expects to achieve positive adjusted EBITDA of $5 million, investors appear concerned about the company's ability to rein in losses and achieve profitability.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。